<DOC>
	<DOC>NCT00975299</DOC>
	<brief_summary>Visual assessment of diagnostic PET/CT (positron emission tomography/computed tomography) images obtained after a single intravenous injection of BAY86-4367 in patients with cancer</brief_summary>
	<brief_title>Positron Emission Tomography/Computed Tomography (PET/CT) Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-4367 in Patients With Prostate Cancer and Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Bombesin</mesh_term>
	<criteria>Healthy volunteers: males, &gt;/=50 and &lt;= 65 years of age Cancer patients: males &gt;/= 45 years of age patients with recurrent prostate cancer had a positive choline PET/CT for detection, or staging, or restaging of cancer, evaluation of the primary prostate cancer detection rate with BAY 864367 in comparison to histology as standard of truth (choline PET/CT is optional). Exclusion criteria for all healthy volunteers and patients: Concurrent severe and/or uncontrolled and/or unstable other medical disease (e.g. poorly controlled diabetes, congestive heart failure, myocardial infarction within 12 months prior to planned injection of BAY 864367, unstable and uncontrolled hypertension, chronic renal or hepatic disease, severe pulmonary disease) which could compromise participation in the study Known sensitivity to the study drug or components of the preparation.</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Neoplasm</keyword>
	<keyword>PET/CT diagnosis</keyword>
	<keyword>PET tracer</keyword>
</DOC>